Categories
All News Energy World

Remote Patient Monitoring Devices Market to Garner US$ 1,544.94 Mn by 2027 with Welch Allyn, Resideo Technologies (Honeywell Life Care), Abbott Laboratories, Biotronik SE & Co. KG, Masimo Corporation

The Remote Patient Monitoring Devices Market accounted to US$ 712.21 Mn in 2018 and is expected to grow at a CAGR of 9.3% during the forecast period 2019 – 2027, to account to US$ 1,544.94 Mn by 2027.

Chronic diseases, including heart disease, stroke, diabetes, and obesity, are the leading causes of death in the world and account for most of the nation’s health care costs. According to report of CDC, in 2018, approximately more than 9% of the population has diabetes, which is the leading cause of kidney failure, lower-limb amputations in US. Moreover, the data also suggests that 1.5 million Americans are diagnosed with diabetes every year in the US.

The global Remote Patient Monitoring Devices market has been accurately illustrated in this report with the help of the latest primary and secondary research conducted using best-in-class technology and analysts. The report finds important trends that are used to predict the expected revenues that the market will achieve in the coming years. For each of the different retail categories, the report provided a near-accurate estimate of market growth and other important figures. This can help industry players gain a strong foothold in the market and ensure a lasting rise in the near future.

Get sample report now! @

https://www.theinsightpartners.com/sample/TIPHE100001289/

Top key vendors of Remote Patient Monitoring Devices Market:

  • Koninklijke Philips N.V.
  • GE Healthcare
  • Boston Scientific Corporation
  • Omron Healthcare
  • Medtronic Plc.
  • Welch Allyn
  • Resideo Technologies (Honeywell Life Care)
  • Abbott Laboratories
  • Biotronik SE & Co. KG
  • Masimo Corporation

 REMOTE PATIENT MONITORING – MARKET SEGMENTATION

By Product

  • Vital Sign Monitors
  • Special Monitors

By Application

  • Cardiovascular Diseases Treatment
  • Cancer Treatment
  • Sleep Disorder Treatment
  • Diabetes Treatment
  • Weight Management & Fitness Monitoring

By End user

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Home Healthcare

The statistical data for the Remote Patient Monitoring Devices Market has been compiled using qualitative and quantitative research methodologies that help to make informed decisions in companies. It highlights the dynamics of different work such as drivers, constraints and opportunities. In addition, it provides analytical data for trading features such as domestic consumption, global consumption, import and export. The base year examined the studies and forecast period that analysts considered in this publication. The entire supply and demand chain was examined by researchers.

Request for Buy Report @

https://www.theinsightpartners.com/buy/TIPHE100001289/

Global geographic areas such as North America, Latin America, Asia, the Pacific, Africa and Europe were studied for studies of the dynamic aspects of companies. Various key players have been classified at a high level for in-depth knowledge and useful data for companies. Some key players were reviewed in this research report. Various industry analysis tools such as SWOT and Porter were used in the analysis of the global Remote Patient Monitoring Devices market.

Moreover, it provides a comprehensive snapshot of the global business. To understand the global Remote Patient Monitoring Devices market for the, different heads were clearly tested by researchers. Some important economic facts have been presented in terms of price structure, profit margin and market shares. To provide accurate data, it uses effective graphical presentation methods such as tables, charts, graphs and images. The report highlights new trends, tools and technology platforms that help increase corporate performance.

Table of Content:

Global market Research Report

Chapter 1: Remote Patient Monitoring Devices Market Overview

Chapter 2: market Economic Impact

Chapter 3: Competition by Manufacturer

Chapter 4: Production, Revenue (Value) by Region (2018-2023)

Chapter 5: Supply (Production), Consumption, Export, Import by Regions (2018-2023)

Chapter 6: Remote Patient Monitoring Devices Market Production, Revenue (Value), Price Trend by Type

Chapter 7: market Analysis by Application

Chapter 8: market by Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Remote Patient Monitoring Devices Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Market Effect Factors Analysis

Chapter 12: Market Forecast (2021-2027)

Chapter 13: Appendix

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: [email protected]

Categories
All News

Medical Cyclotron Market Grow Revenue at a US$ 238.21 million by 2027 with  Siemens AG, Advanced Cyclotron Systems, isoSolution Inc, ALCEN, Ionetix Corporation, Best Cyclotron Systems, Inc.

The Medical Cyclotron Market was valued at US$ 180.00 million in 2019 and is projected to reach US$ 238.21 million by 2027; it is expected to grow at a CAGR of 3.6% from 2020 to 2027.

A medical cyclotron is a particle accelerator. It is an electrically powered machine that produces beam of charged particles used for industrial, research, and medical purposes. In medical applications, cyclotrons produce beams that are used to manufacture radioisotopes for the purpose of medical imaging. Various medical cyclotrons are being used for the production of SPECT and Positron Emission Tomography (PET) isotopes used for therapeutic and other medical applications.

Study the global Medical Cyclotron market report with an in-depth overview, describing the scope of the product / industry and illustrating market expectations and status until 2026. Market data analysis study by manufacturers, region, type and application, also analyzes the market situation and market share, growth rate, future trends, market engines , Opportunities and challenges, risk and barriers to entry, sales channels, distributors and analysis of Porter Five Force.

Ask For sample report now! @

https://www.theinsightpartners.com/sample/TIPHE100001233/

Report Covers Medical Cyclotron Market Segment by Top Vendors are:

  • General Electric Company
  • Varian Medical Systems, Inc.
  • IBA
  • Sumitomo Heavy Industries, Ltd
  • Siemens AG
  • Advanced Cyclotron Systems
  • isoSolution Inc
  • ALCEN
  • Ionetix Corporation
  • Best Cyclotron Systems, Inc.

Medical Cyclotron Market By Type:

  • Ring Cyclotron
  • Azimuthally Varying Field (AVF)

Medical Cyclotron Market By Capacity:

  • 10–12 MeV
  • 16–18 MeV
  • 19–24 MeV
  • 24 MeV and Above

Medical Cyclotron Market By End User:

  • Hospitals
  • Specialized Clinics
  • Pharmaceutical Companies
  • Other End User

The report also creates a clear picture of the various factors that will drive the global Medical Cyclotron market in the years to come. In order to help companies spot potential threats and to give them a clear picture of the opportunities that exist in the Insurance market, the report offers a SWOT analysis of the global market. For the purpose of the study, market analysts have employed rigorous primary and secondary research techniques.

Request for Buy Report @

https://www.theinsightpartners.com/buy/TIPHE100001233/

Further in the report, the Medical Cyclotron market is examined for Sales, Revenue, Price and Gross Margin. These points are analyses for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Medical Cyclotron Market consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Table of Content of Medical Cyclotron Market:-

Chapter 1 Introduction and Overview

Chapter 2 Industry Strategy and Economic Impact

Chapter 3 Rising Trends and New Strategy with Major Key players

Chapter 4 Global Market Analysis, Trends, Growth Factor

Chapter 5 Medical Cyclotron Market Application and Business with Potential Analysis

Chapter 6 Global Market Segment, Type, Application

Chapter 7 Global Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion of Medical Cyclotron Market

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: [email protected]

Categories
All News

Is genomics revolution all fun and games? How blockchain can calm data security nerves! | Roots Analysis

Have you had your genomics sequenced? If you asked this question a few years ago, people would have thought you were crazy. However, today, genetic tests are up for sale in supermarkets! Fifteen years ago, the first ever Human Genome Project was carried out, which took more than 13 years to complete.

For More Insights Click Here

This (Human Genome Project) costed more than USD 3 billion and required joint efforts of hundreds of scientists across the globe. The completion of the project offered brilliant insights into the entire structure of the genome; including its length, sequences, protein-coding genes, structural variants and a large number of repeats and noncoding sequences which were originally believed to be ‘junk DN

Thanks to the advent of advanced NGS technologies in the past decade, it now costs under USD 1,000 and takes less than a week for an individual to have his or her genome sequenced. What’s more? They can even order a test online themselves.

Today, researchers are talking about sequencing the genomes of a million people on the planet. The rate of progress in genomics development resembles that of Moore’s Law in processor development – but it is just the beginning. With plethora of molecular level personalized data available in the hands of research groups, molecular-diagnostics companies are uniquely positioned to unravel value.

However, the entire spectrum of value can only be unlocked, if appropriate data integration and analytics capabilities are possessed by stakeholders. These include capabilities that link genetic data with other health indicators, such as medical records and even non-medical information. As the volume of data magnifies with time, and the level of analysis becomes increasingly sophisticated, both start-ups and established technology players with core competencies in advanced analytics are anticipated to venture into the genomics space. Companies such as Emerge and Ignite have already begun using genomic data linked to EMR for personalized medicine.

However, before genomic data can be utilized to its full-blown potential, additional questions regarding data privacy and security need to be answered.

Who can have access to this enormous amount of data and how do research groups, companies and government bodies ensure that genomic data doesn’t end up in the wrong hands?

World’s leading consumer genetics and research companies such as 23andMe and Ancestry.com have come under the scrutiny of Federal Trade Commission, which has a page dedicated to listing all the risks associated with sending one’s genomic data to companies like 23andMe.

In this scenario, blockchain technology has emerged as a plausible saviour for pharma’s woes. In November 2018, Encrypgen launched the world’s first genomic data marketplace, called the Gene-Chain, a cryptographically encoded ledger used to the searching, storing, buying and selling of genomic data. It is a private network, implying that users must join the community to participate. This helps in preserving the anonymity of users, create abstraction between users and their data for privacy and protection of identity, as well as process the available genetic data files through indexing.

Further, blockchain companies are offering tokens, a form of currency for exchange of data in order to incentivize the process, allowing users to have access to their products or services. With the ever-expanding and all-consuming web of hackers across the globe, protecting genomic data is one of the top concerns in the world today. Unlike credit cards and passport numbers hacks, which can be dealt with, genomic data breach is a one strike ballgame.

 

For further information, check out the report here

 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News

Growth Drivers and Roadblocks in Targeted Protein Degradation Market | Roots Analysis

In a recent article, I discussed the rise of protein degradation therapeutics and the surge in big pharma interest in this emerging space. With more than 3,600 tweets posted over the last three years to over 5,000 articles published over the last decade, the concept of protein degradation has got the right people talking.

For More Insights Click Here

In contrast to the traditional small molecule inhibitors and antibody drugs, protein degraders are designed to develop drug candidates for many intractable diseases that other therapeutic modalities cannot address.

Owing to extensive research in this domain, multiple protein-degradation-focused biotech firms have emerged with ample funding. In addition, big pharma companies, including Boehringer Ingelheim, Celgene, Novartis, and Pfizer have launched internal efforts and forged partnerships to explore the modality. Recently, Boehringer Ingelheim and the University of Dundee extended their collaboration for the development of PROTAC based drugs to treat cancer, building on the success of their ongoing alliance. Similarly, Novartis collaborated with the University of California, Berkeley to establish the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. The center combines Novartis’ expertise in chemical biology with Berkeley’s expertise in covalent chemoproteomics.

To say that this space is growing would be an understatement. The potential to drug the undruggable is just far too more lucrative to let a few roadblocks come in the way. Here is a look at some of the key growth drivers and roadblocks in the targeted protein degradation space:

For further information, check out the report here

 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News

CMO, CMO Everywhere, Not a Single One That Fits: The Reality of Biopharma Contract Manufacturing Market | Roots Analysis

I was recently involved in a discussion with the global outsourcing manager of one of the big pharma companies. The premise of the discussion was around the criteria that big Biopharma Contract players follow for choosing a supplier for their products. One key question that came up in the discussion was whether one-stop-shops are really the go-to companies for outsourcing. And the answer, to a certain extent, validated some of the hypotheses that we had developed internally.

For More Insights Click Here

To give you a background, in one of our market research reports, we had looked at the biopharma contract manufacturing market and identified close to 250 companies that offer biopharmaceutical contract manufacturing services. A number of these companies claim to offer end-to-end services across the value chain of the biopharmaceutical product. The majority of these one-stop-shop companies are those CDMOs that have actively made acquisitions and altered business models to get into a particular space.

However, the one-stop-shop business model doesn’t seem to be that attractive anymore. Initially, we witnessed the issues of overcapacity at some of the one-stop CMOs that made the overall operations less profitable. However, now, the one-stop-shop pitch seems nothing more than a pure marketing strategy (not to say that there are no one-stop CMOs). Except for a few top-tier CMOs (that are generally on the preferred supplier list of the majority of big pharma players), it is very difficult to validate that other CMOs actually have the same level of expertise across all the steps in the manufacturing value chain.

Horses for Courses – A better strategy?

An interesting article that I had read on this subject was by Louis Garguilo, Chief Editor, Outsourced Pharma. In his article, he presented interesting examples of why the horses for courses strategy works better than a one-stop-shop business model. One interesting section from his article that supports the argument is – If your project suffers setbacks (with a one-stop-shop) on the drug product side, your relationship on the synthesis side will also suffer. In other words, a breakdown of the relationship, or unforeseen challenges, for anyone part of your project can result in a breakdown of the entire relationship. Given the years of effort and investment that goes into developing a product, it is never a good strategy to put all your eggs in the same basket, or in other words, rely on just one supplier to decide your returns from the innovative product.

To summarize my discussion, I would say that while the biopharma companies are still figuring out what is the best business model moving forward, it is high time that companies move away from I do everything pitch to focusing on their actual unique selling points/expertise. This will make the sourcing decision much easier and establish more clarity in the industry.

 

For further information, check out the report here

 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News

Catalent’s Shopping List: Hinting Towards a One-Stop Cell & Gene Therapy CMO in Making | Roots Analysis

There appear to be no Monday blues for Catalent as the company announces the acquisition of MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization. Following its last year’s acquisition of Paragon Bioservices (a leading viral vector developer), Catalent’s recent acquisition has extended the company’s leadership in this already crowded space.

For More Insights Click Here

Why has there been so much interest in this space?

The increasing acquisition activity in this space is heavily driven by the growing pipeline of cell-based therapies. With more than 600 candidates in development, the cell therapy space has witnessed significant interest from various stakeholders.

The development pipeline of cell-based therapies is very attractive and features a number of big pharma players. However, the manufacturing challenges associated with these therapies has acted as a roadblock.

Manufacturing cell therapies is technically and financially demanding. Therefore, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers. In fact, over 100 industry players and 60 non-industry players currently claim to manufacture different types of cell therapies.

Why is Catalent acquiring so many players in gene therapy?

The acquisition of MaSTherCell is a strategic move to extend the service offerings for cell and gene therapies. Here is what the company’s CEO said about the acquisition:

“MaSTherCell extends our leadership position in the biotech industry, complements our leading gene therapy offering, and allows us to deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions for innovators across the large molecule space”

– John Chiminski, Catalent’s Chair & Chief Executive Officer

The move has allowed the company to set itself apart in the highly competitive cell and gene therapy manufacturing space.

 

For further information, check out the report here

 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News

Evolution of Cancer Diagnostics: Rise of Novel Non-Invasive Methods | Roots Analysis

When a big pharma agrees to spend millions in acquiring a drug discovery company, the world is bound to take note. The same happened earlier this year – the acquisition of Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) was a piece of big news in the drug discovery world, validating the potential of DNA encoded libraries in drug discovery.

For More Insights Click Here

The acquisition has allowed Amgen to get a team of experts adept at making and screening billions to trillions of compounds to find promising leads. And Amgen is not the only pharma company that has realized the benefits of this technology. As per a recent study by Roots Analysis, close to 100 strategic partnerships related to DNA-encoded libraries have been forged between pharma players and academic institutes and/or technology providers during the period 2010-2019. The rise in partnership activity is a clear indicator of the increasing popularity of this unique technology. Here, we will look at some of the key trends that are shaping up this industry:

What are DNA encoded libraries?

DNA-encoded compound libraries are a highly attractive technology for the discovery of small-molecule protein ligands. These compound collections consist of small molecules covalently connected to individual sequences carrying readable information about the compound structure. DNA-tagging allows for efficient synthesis, handling, and interrogation of vast numbers of chemically synthesized, drug-like compounds. Here is a perfect video describing the principle behind DNA encoded libraries.

When was the concept first introduced?

While the first small molecule PROTAC was developed in 2008, the history of targeted degradation goes back to 1992. The figure below presents an illustrative overview of the evolution of targeted protein degradation.

What are the benefits of targeted protein degradation?

The concept of  encoded libraries was introduced 25 years ago by Richard Lerner, a chemist at Scripps Research Institute California, and his colleague Sydney Brenner, co-winner of the 2002 Nobel Prize in Physiology or Medicine. The pair published a paper that’s often described as a thought experiment. They also made a small encoded library and patented the idea around the same time.

How many DNA encoded libraries are currently available to the pharma players to choose from?

According to Roots Analysis, presently, nearly 30 DNA-encoded libraries are available to various pharmaceutical companies for the purpose of drug discovery. The majority of the encoded libraries are designed to identify leads against protein pump inhibitors which are otherwise difficult to screen using traditional libraries. However, with respect to the type of pharmacological leads, over 20 libraries are designed for the discovery of small molecules, followed by macrocycles.

Which companies offer DNA encoded libraries for drug discovery?

The market is highly fragmented, featuring a mix of small-sized companies (less than 50 employees, 48%), mid-sized companies (more than 51 employees, 20%), large companies (more than 500 employees, 8%) and very large companies (more than 5,000 employees, 24%) that offer DNA-encoded libraries. Notable examples of well-established players include (in alphabetical order, no selection criteria), Amgen (through the acquisition of Nuevolution), ETH Zurich and GSK (through the acquisition of Praecis Pharmaceuticals). The recent launch of the Encoded Library (DEL) service package DELight WuXi AppTec is another example of big players entering this space.

For further information, check out the report here

 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News

A Pizza Hut Prescription for Gene Therapy Companies | Roots Analysis

As we enter 2020, one drug class that is set to take-off is gene therapy. With three approvals (Zolgensma® (US), Zynteglo™ (Europe) and Beperminogene Perplasmid (Japan), 2019 was a break out year for gene therapy developers. The $16 billion-plus investment by various investors finally seems to be paying off as we enter 2020 with am.,

For More Insights Click Here

While several positives make us all very optimistic about the future of gene therapies, there are a few challenges that must be addressed before these therapies can achieve their true potential. Challenges related to pipeline development, platform selection, manufacturing, and reimbursement are amongst the top hurdles that these companies are currently facing. Also, the challenges related to supply chain and logistics are beginning to arise as these therapies reach the market.

These logistical challenges are more pronounced when products are to be distributed to international markets. Given the lack of experience specific to gene therapies in the industry, the networks may not be as developed, and delay times at ports of entry may be ruinous to products with limited shelf lives. A few other industries that have faced such logistic issues in the past are – the food delivery market, and the rental cabs or bookings market. Earlier, it had become so difficult to track the status of your pizza order. But now, with the rise of mobile applications, you can track the progress in real-time.

Let us imagine a scenario wherein you are celebrating the new year’s eve with your family. You have decided to order pizzas for the family from this amazing restaurant. You call the restaurant and place the order. The restaurant confirms your order and then the wait begins. 10 minutes….20 minutes…30 minutes pass and you have no idea where your order is. The new year celebration excitement suddenly turns to anxiety and you are worried and unsure about when can you exactly expect your pizza.

Now let us think about what happens to a patient that is eligible for a gene therapy treatment. Given the exhaustive inclusion criteria, only a limited number of patients qualify for these therapies, and once they qualify, the wait begins. And it is not just the patient who is waiting, their entire family, along with the doctors are anxiously waiting for that personalized dose of cells to be delivered at the hospital bed that can finally cure the disease. If we are ready to stretch our imaginations, this wait and anxiety that the patient faces can easily be compared to the pizza hut craving that you were having on the new year’s eve.

The solution – simple. Get an App!!

Do what every company seems to be doing these days. Make personalized therapies even more personalized. Get an app that tells the patient the whereabouts of their therapy across the supply chain. Give the patient some control and deliver not just a therapy, but an experience.

Some of the players, such as (illustrative list) Trakcel, Veeva, Be the Match BioTherapies, are already deploying solutions that can be used to efficiently manage and streamline various aspects of the complex supply chains of cell and advanced therapies. Presently, there are more than 160 innovative software-enabled systems for managing the cell and advanced therapies supply chain.

For further information, check out the report here

 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News

Coronavirus: The World Must Unite In Its Fight | Roots Analysis

A lot has happened. And that too in a short span of time. A few weeks ago, everyone outside China was worried about the quarantined cruise ships. No one at that stage would have thought that, just in a few days, the virus may be knocking at the doorsteps. Now there is fear and it is real. There seems to be chaos everywhere – Whether it is the authenticity of facts being shared, the crash in the global stock markets or the uncertainty that looms for small (and large) businesses worldwide.

Being a father of two kids, I am obviously worried about them. I am also worried about my parents who are in late 60s. Over the last few days, both me and my wife have been educating everyone to take necessary precautions. Where I live, there hasn’t been any confirmed case yet; however, it just appears to be a matter of time before we hear the dreaded news. I went to a hospital today to meet one of my relatives and I could see everyone worried. It is a great sign that some people are taking precautions; at best, what you can do in your individual capacity is to be aware of your surroundings and maintain the basic personal hygiene. However, at the same time, it is obvious that a lot more is required if the world stands any chance of fighting it out.

For More Insights Click Here

Hats off to WHO – guys, you are doing a fantastic job keeping us updated. Bill & Melinda Gates Foundation – Well done again! Delivering at home coronavirus tests. All researchers across the globe– You must keep working hard and you must know that you could end up being the savior.

Despite all the efforts being put in by several organizations, the failure (if indeed it is a failure) will be not because we weren’t able to develop a vaccine in time but primarily because some of us have been selfish (e.g. by not revealing our travel history OR by ignoring the flu symptoms) and inadvertently becoming an agent spreading the virus further. This to me appears to be the biggest roadblock in the fight against this impending pandemic. Do you care about humanity? For the first time, at least in my lifetime, I feel that I (and you) have a major role to play in preventing a major disaster unfolding on this planet. And I’ll fight it out. We all must fight it out together. Let’s take up this moral responsibility by just being more aware of what it is and force ourselves not to become the agents in spreading this further. If we are united in this fight, the victory will be ours even if it takes some time and patience to get to the other side!

 

For further information, check out the report here

 

Read more at:

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News

Nurix betters Kymera: The Targeted Protein Degradation War Is Heating Up | Roots Analysis

It is not very common to hear venture capital firms back competitors in the same week. It happened yesterday with Nurix announcing a USD 120 million backing yesterday, immediately after Kymera had grabbed an almost similar amount earlier this week. This does tell us something about the field of Targeted Protein Degradation! Read on.

For More Insights Click Here

How crowded is the field of Targeted Protein Degradation?

The current pipeline features over 85 small molecule protein degraders that are being evaluated for multiple disease indications. A total of USD 3.5 billion has already been poured in by venture capital and strategic investors. And the work that we have done in this space tells us that 100+ partnerships, primarily for R&D purposes, have already been inked.

Can we measure the clinical activity?

Yes, we believe over 5500 patients are already enrolled in clinical trials worldwide. North America is the hub with over 60% of the patient registrations. It is also important to highlight that within the US, California, Massachusetts, New York, and Connecticut, have emerged as the most important regions where multiple developers are presently located

Are the Big Pharma missing out?

Start-ups, such as Nurix and Kymera, are driving the show so far. THere are several other small companies that are trying to drive home the first mover advantage. In addition, we know of at least 10 big pharma companies have already taken the initiatives in this space. These include Genentech, AbbVie, Boehringer and Novartis.

What is the Size of the Prize?

There are no definitive numbers. However, our analysis suggests that it is likely to be huge in the long term. Specifically, the revenues generating from licensing the technologies, designed for developing targeted protein degraders will be in multiples of billion dollars. Technologies that are intended for use in oncological disorders currently capture a relatively higher market share. By 2030, this domain is likely to be driven by neurodegenerative disorders (such as Alzheimer’s disease and Parkinson’s disease).

 

For further information, check out the report here

 

Read more at:

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]